Clinical trials: Anti-PD-1
Advanced Solid Tumor
Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.
- Trial name
- NCT04282278
- Testing
- Camrelizumab/sintilimab+ Standard chemotherapy, Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）, Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Hebei Medical University Fourth Hospital
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Tracheal Squamous Cell Carcinoma
Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab + carboplatin + paclitaxel in 15 newly diagnosed patients with tracheal malignant tumors.
- Trial name
- NCT04716751
- Testing
- Toripalimab
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small Cell Lung Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended…
- Trial name
- DeLLphi-313 (NCT07531095)
- Testing
- ZL-1310, Tarlatamab, Durvalumab
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Advanced Solid Tumor
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in…
- Trial name
- NCT05199753
- Testing
- LM-108, An Anti-PD-1 Antibody
- Where
- 6 sites in Australia
- Volunteers
- 78 people
- Sponsor
- LaNova Australia Pty Limited
Colo-rectal Cancer, PD-1 Inhibitor
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR…
- Conditions
- Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
- Trial name
- NCT06865521
- Testing
- Akkermansia Probiotics
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- West China Hospital
Advanced Solid Tumors
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate Safety and tolerability of MASCT-I in patients with advanced solid tumors, either alone or in combination with chemical drugs or in combination with PD1 antibody.
- Trial name
- NCT03034304
- Testing
- MASCT-I, Ifosfamide, PD1 antibody
- Where
- 9 sites in China
- Volunteers
- 105 people
- Sponsor
- HRYZ Biotech Co.
Melanoma
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling pathways are not redundant.
- Trial name
- NCT04756934
- Testing
- HX008, LP002
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
Advanced Malignant Tumors(Stage IA-IB)
A Study of AK129 in Patients With Advanced Malignant Tumors
A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors
- Trial name
- NCT05645276
- Testing
- AK129 IV infusion
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Akeso
Multiple Myeloma
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with…
- Trial name
- NCT03357952
- Testing
- Daratumumab, JNJ-63723283
- Where
- 13 sites in Belgium, Israel and 1 more
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer Metastatic
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06682247
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Feng Wang
Advanced Malignant Tumors
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1…
- Trial name
- NCT05223231
- Testing
- LBL-019 Injection, anti-PD-1 antibody injection
- Where
- 6 sites in China
- Volunteers
- 26 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Metastatic Melanoma
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well olaparib in combination with pembrolizumab works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT04633902
- Testing
- Olaparib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Solid Tumors
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
This study is open to Japanese adults with different types of advanced cancer (solid tumors). People can join the study if their cancer has spread, and previous treatments were not successful or no treatments exist.
- Trial name
- NCT07176975
- Testing
- BI 1831169, nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies the side effects and best dose of ipilimumab, nivolumab, and radiation therapy and how well they work in treating patients with advanced human papillomavirus (HPV) positive oropharyngeal squamous cell…
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma
- Trial name
- NCT03799445
- Testing
- Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Refractory DLBCL
Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)
To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL
- Trial name
- PCR (NCT05115409)
- Testing
- Anti-PD-1 Antibody Plus Chidamide and Rituximab
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Relapsed/Refractory Lymphoma
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese patients with relapsed/refractory lymphoma .
- Trial name
- NCT05189093
- Testing
- Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Malignant Solid Tumour
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.
- Trial name
- NCT02843204
- Testing
- Pembrolizumab, NK immunotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04214249
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms by Site
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the…
- Trial name
- NCT01629758
- Testing
- Denenicokin, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.